Department of Hepatobiliary and Pancreatic Surgery, Huangshi Central Hospital of Edong Healthcare Group, Hubei Polytechnic University, Huangshi, China.
Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Scinecne and Technology, Huangshi, China.
J Clin Lab Anal. 2020 Jun;34(6):e23213. doi: 10.1002/jcla.23213. Epub 2020 Mar 5.
The presented study aimed to investigate the association of A-kinase interacting protein 1 (AKIP1) expression with tumor properties, liver functions, cancer markers, and overall survival (OS) of hepatocellular carcinoma (HCC) patients.
A total of 432 HCC patients receiving surgery were retrospectively reviewed in our study. Clinical characteristics of patients were obtained. Tumor tissue specimens of all patients were collected, and AKIP1 expression was evaluated by immunohistochemistry (IHC) assay. OS was assessed, and the median follow-up duration was 35.0 months. AKIP1 high expression was defined as total IHC score more than 3 and was further graded as AKIP1 high+ (IHC 4-6), AKIP1 high++ (IHC 7-9), and AKIP1 high+++ (IHC 10-12).
About 265 (61.3%) patients presented with AKIP1 low expression and 167 (38.7%) patients had AKIP1 high expression. AKIP1 high expression correlated with higher performance status score (P = .006), largest tumor size ≥5.0 cm (P < .001), Barcelona clinic liver cancer (BCLC) stage B (vs stage A; P = .024), increased alpha-fetoprotein level (P = .036), and higher carbohydrate antigen 199 level (P < .001). AKIP1 high expression (P < .001) and increased AKIP1 expression grade (P < .001) both correlated with worse OS, and Cox's regression analyses revealed that AKIP1 high expression (P < .001) was an independent predictive factor for shorter OS. In subgroup analysis, AKIP1 high expression and more advanced AKIP1 expression grade associated with worse OS in both BCLC stage A subgroup patients (both P < .001) and BCLC stage B subgroup patients (both P < .001), respectively.
AKIP1 is a novel and promising biomarker for disease monitoring and prognosis in HCC patients.
本研究旨在探讨 A 激酶相互作用蛋白 1（AKIP1）表达与肝癌患者肿瘤特性、肝功能、肿瘤标志物和总生存期（OS）的关系。
本研究回顾性分析了 432 例接受手术治疗的肝癌患者。收集患者的临床特征，采用免疫组织化学（IHC）法检测肿瘤组织标本中 AKIP1 的表达。评估 OS，中位随访时间为 35.0 个月。AKIP1 高表达定义为总 IHC 评分>3，进一步分为 AKIP1 高+（IHC 4-6）、AKIP1 高++（IHC 7-9）和 AKIP1 高+++（IHC 10-12）。
约 265 例（61.3%）患者 AKIP1 低表达，167 例（38.7%）患者 AKIP1 高表达。AKIP1 高表达与较高的体能状态评分（P=0.006）、最大肿瘤直径≥5.0cm（P<0.001）、巴塞罗那临床肝癌（BCLC）分期 B（与 A 期相比；P=0.024）、甲胎蛋白水平升高（P=0.036）和癌抗原 199 水平升高（P<0.001）相关。AKIP1 高表达（P<0.001）和 AKIP1 表达分级增加（P<0.001）均与 OS 较差相关，Cox 回归分析显示 AKIP1 高表达（P<0.001）是 OS 较短的独立预测因素。亚组分析显示，在 BCLC 分期 A 组患者（均 P<0.001）和 BCLC 分期 B 组患者（均 P<0.001）中，AKIP1 高表达和更高级别的 AKIP1 表达分级均与 OS 较差相关。
AKIP1 是一种新型有前途的肝癌患者疾病监测和预后标志物。
